FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to pharmaceutics and concerns a liposomal composition containing eribuline or its pharmaceutically acceptable salt, as well as a method for preparing it.
EFFECT: invention provides high stability of the liposomal composition.
39 cl, 3 dwg, 7 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
| TUMOUR TREATMENT AGENT AND KIT CONTAINING LIPOSOMAL GEMCITABINE COMPOSITION | 2016 |
|
RU2761620C2 |
| AGENT FOR TREATING A TUMOR AND A KIT CONTAINING A LIPOSOMAL COMPOSITION OF GEMCITABINE | 2016 |
|
RU2738365C2 |
| AGENT FOR TREATING TUMOUR AND KIT CONTAINING LIPOSOMAL COMPOSITION OF GEMCITABINE | 2016 |
|
RU2768178C2 |
| LONG-ACTING CONTROLLED RELEASE LIPOSOMAL COMPOSITION AND METHOD FOR PRODUCING IT | 2012 |
|
RU2571077C2 |
| READY-TO-USE FORMULATION FOR LIPOSOMAL INJECTION OF VINCRISTINE SULFATE | 2016 |
|
RU2676762C1 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
| LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
| AGENT IMPROVING ANTI-CANCER EFFECT AND CONTAINING LIPOSOMAL AGENT CONTAINING OXALIPLATIN, AND ANTI-CANCER AGENT CONTAINING LIPOSOMAL AGENT | 2009 |
|
RU2492863C2 |
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
